0001564590-21-059888.txt : 20211209 0001564590-21-059888.hdr.sgml : 20211209 20211209161121 ACCESSION NUMBER: 0001564590-21-059888 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211208 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211209 DATE AS OF CHANGE: 20211209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Talis Biomedical Corp CENTRAL INDEX KEY: 0001584751 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40047 FILM NUMBER: 211482069 BUSINESS ADDRESS: STREET 1: 230 CONSTITUTION DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-433-3000 MAIL ADDRESS: STREET 1: 230 CONSTITUTION DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: SlipChip Corp DATE OF NAME CHANGE: 20130820 8-K 1 tlis-8k_20211208.htm 8-K tlis-8k_20211208.htm
false 0001584751 0001584751 2021-12-08 2021-12-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 8, 2021

Talis Biomedical Corporation

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Delaware

 

001-40047

 

46-3122255

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

230 Constitution Drive

Menlo Park, California 94025

(Address of principal executive offices, including zip code)

(650) 433-3000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

TLIS

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Resignation of Chief Executive Officer and Director

On December 8, 2021 (the “Effective Date”), Brian J. Blaser tendered his resignation as the President and Chief Executive Officer of Talis Biomedical Corporation (the “Company”) and a member of the Board of Directors of the Company (the “Board”) to be effective immediately.

Appointment of Chief Executive Officer and Director

On December 8, 2021, the Board appointed Robert Kelley as (i) Chief Executive Officer of the Company and (ii) a member of the Board to fill the vacancy created by Mr. Blaser’s resignation, to serve as a Class II director with an initial term expiring at the Company’s 2023 Annual Meeting of Stockholders, in each case, effective on the Effective Date.

Mr. Kelley has more than 25 years of commercial leadership experience in the biotechnology industry and has served as the Company’s Chief Commercial Officer since September 2020. From October 2017 to August 2020, Mr. Kelley was Vice President, Sales and Commercial Development of Genalyte, Inc., a healthcare analytics and point-of-care diagnostics company. Prior to Genalyte, Mr. Kelley was Vice President, Marketing of Cardiff Oncology, Inc. (formerly Trovagene, Inc.), a publicly held liquid biopsy company, from March 2015 to May 2017. From December 2008 to March 2015, Mr. Kelley held various positions of increasing responsibility with Illumina Inc., a publicly held biotechnology company, including Global Sales Manager for clinical applications of Next-Generation Sequencing and Director, Market Development, New and Emerging Opportunities. Mr. Kelley received a B.S. in Biology from Duke University and an M.B.A. from the UCLA Anderson School of Management. The Board believes that Mr. Kelley’s experience as the Company’s Chief Commercial Officer and his extensive commercial leadership experience in the biotechnology and diagnostics industry qualify him to serve on the Board.

In connection with Mr. Kelley’s appointment as Chief Executive Officer, the Company entered into an offer letter with Mr. Kelley that governs the terms of his employment with the Company. Among other things, the offer letter provides for an annual base salary of $525,000 and an annual target bonus equal to 75% of his annual base salary. Mr. Kelley will also be entitled to certain travel and housing reimbursements in connection with his weekly travel from his remote working location to one of the Company’s facilities. Pursuant to the offer letter, Mr. Kelley will be granted a stock option to purchase 450,000 shares of the Company’s Common Stock. The option will be issued pursuant to the Company’s 2021 Equity Incentive Plan and will vest over a four-year period, with 25% of the shares subject to such option vesting on the one-year anniversary of the Effective Date and the balance of the shares subject to such option vesting in equal installments over the following 36 months.

Mr. Kelley will be eligible to participate in the Company’s Severance and Change in Control Plan (a copy of which is filed as Exhibit 10.6 to the Company’s Registration Statement on Form S-1 (File No. 333-252360), filed with the Securities and Exchange Commission on February 8, 2021).  There are no transactions between the Company and Mr. Kelley that require disclosure under Item 404(a) of Regulation S-K. Further, there is no arrangement or understanding between Mr. Kelley and any other persons pursuant to which Mr. Kelley was selected as an officer and director of the Company.

The foregoing description of Mr. Kelley’s offer letter is not complete and is qualified in its entirety by reference to the text of the offer letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

Item 9.01.Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit

Number

 

Description

 

 

 

10.1

 

Offer Letter, dated December 8, 2021, by and between the Company and Robert Kelley.

104

 

Cover Page Interactive Data File (Embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date: December 9, 2021

 

 

 

TALIS BIOMEDICAL CORPORATION

 

 

 

 

 

 

 

 

By:

 

/s/ J. Roger Moody, Jr.

 

 

 

 

 

 

J. Roger Moody, Jr.

 

 

 

 

 

 

Chief Financial Officer

 

 

 

 EX-10.1 2 tlis-ex101_6.htm EX-10.1 tlis-ex101_6.htm

 

 

Exhibit 10.1

 

 

 

8 DECEMBER 2021

 

Dear Robert,

 

It is with great enthusiasm that Talis Biomedical Corporation (“Talis” or the “Company”) is providing you an offer for continued employment in the full-time position of Chief Executive Officer, reporting to the Company’s Board of Directors (the “Board”), under the terms of this offer letter agreement (the “Agreement”), and effective as of the date you have signed and returned this Agreement to the Company (the “Effective Date”). In addition, you will be appointed to the Board effective as of the Effective Date.

 

We are pleased to increase your base salary to the rate of $525,000.00 per year, which will be paid in accordance with the Company’s normal payroll practices. The target annual bonus for this position is 75% of your base salary rate, beginning in calendar year 2022. For 2021, you will continue to be eligible for a discretionary annual bonus under your existing employment arrangement and targets as the Company’s Chief Commercial Officer. All payments to you from the Company will be subject to standard payroll deductions and applicable withholdings. You must be employed through the date bonuses are paid to employees to earn any such bonuses. Your primary work location shall be the Company’s main offices in Menlo Park, California and Chicago, Illinois, provided that the Company reserves the right to require you to perform your duties at places other than your primary work location from time to time, and to require reasonable business travel.

 

The Company will reimburse you for weekly travel from your home in Miami, Florida to one of your primary Company work locations, (e.g. Menlo Park or Chicago), pursuant to our expense reimbursement policies and practices as in effect from time to time. As an additional benefit, the Company will pay you an amount intended to cover your housing while away from your home working at your primary work location, which amount shall be based on your actual costs incurred and will in no event be more than $7,000 per month. The travel reimbursement payments and housing allowance may be subject to applicable deductions and withholdings and will be subject to a tax gross up, to the extent such payments are taxable to you.

 

The Company may change your compensation, benefits, position, duties and work location from time to time at its discretion.

 

 

 

 

 

 

 

Any prior equity awards previously granted to you will continue to be governed by the applicable equity incentive plan and grant documents. In addition, subject to approval by the Board (or the Compensation Committee of the Board), on the Effective Date, you will be granted a stock option (the “Option”) to purchase 450,000 shares of the Company’s common stock. The Option shall be an incentive stock option to the maximum extent permissible under Section 422 of the Internal Revenue Code of 1986, as amended. The exercise price per share of the Option shall be equal to the closing price of common stock of the Company on the date of grant. Subject to your continued services to the Company, the Option will vest over the four-year period following the Effective Date as follows: twenty-five percent (25%) shall vest on the twelve (12) month anniversary of the Effective Date and the remainder shall vest monthly over the following thirty-six (36) months. The Option will be granted pursuant and subject to the Company’s 2021 Equity Incentive Plan and the standard form of stock option agreement thereunder.

 

You will continue to be eligible for Company benefits, which currently include medical, dental and vision insurance, as well as other Company benefits, for you and your eligible dependents, subject to plan terms and generally applicable Company policies. We also currently offer a 401(k) with a Company match as well as a Paid Time Off (PTO) program and paid Company holidays. You will accrue PTO at the rate of 4 weeks (20 days) per year, subject to the Company’s PTO policies in effect from time to time.

 

You will be eligible to participate in the Talis Biomedical Corporation Severance and Change in Control Plan, at the Chief Executive Officer level, pursuant to the terms and conditions of a participation agreement (if approved and executed by you and the Company) and other applicable plan documents. If prior to the Effective Date you were eligible for any severance benefits under a prior participation agreement or other plan, policy or agreement (if any, the “Prior Arrangements”), then you acknowledge and agree that this agreement supersedes any Prior Arrangements and such Prior Arrangements are hereby waived and extinguished and you are no longer eligible for nor entitled to any severance or other benefits under them. You further acknowledge and agree that the changes to your employment, as set forth in this Agreement, do not constitute “Good Reason” or any other grounds for you to resign your employment or otherwise obtain severance benefits under any Prior Arrangements.

 

Please note that your continued employment with the Company is for no specified period and constitutes “at-will” employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to terminate its employment relationship with you at any time, for any reason or for no reason.

 

2

 

 

 

 

 

As a Company employee, you will continue to be expected to abide by Company rules and policies. Your prior signed Employee Confidential Information and Inventions Agreement remains in full force and effect and binding upon you.

 

This Agreement, together with your Employee Confidential Information and Inventions Assignment Agreement, forms the complete and exclusive statement of your continued employment with the Company. It supersedes any other agreements or promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly reserved to the Company’s discretion in this letter, require a written modification signed by an officer of the Company. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This Agreement may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.

 

* * * * *

 

3

 

 

 

 

 

We look forward to continuing to work with you and hope you will find your continued employment at Talis a wonderfully rewarding and enjoyable experience.

 

 

Best Regards,

 

/s/ Felix Baker

Felix Baker
Chairman of the Board of Directors
Talis Biomedical Corporation

 

 

 

Offer Letter Acceptance

I have read and accept this offer of employment:

 

 

/s/ Robert Kelley

 

December 8, 2021

Robert Kelley

 

Date

 

4

 

 GRAPHIC 3 gxe5r01pklcb000002.jpg GRAPHIC begin 644 gxe5r01pklcb000002.jpg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end GRAPHIC 4 gxe5r01pklcb000001.jpg GRAPHIC begin 644 gxe5r01pklcb000001.jpg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tlis-20211208.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 tlis-20211208_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 7 tlis-20211208_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 tlis-8k_20211208_htm.xml IDEA: XBRL DOCUMENT 0001584751 2021-12-08 2021-12-08 false 0001584751 8-K 2021-12-08 Talis Biomedical Corporation DE 001-40047 46-3122255 230 Constitution Drive Menlo Park CA 94025 (650) 433-3000 false false false false Common Stock, $0.0001 par value per share TLIS NASDAQ true false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Dec. 08, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 08, 2021
Entity Registrant Name Talis Biomedical Corporation
Entity Central Index Key 0001584751
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-40047
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-3122255
Entity Address, Address Line One 230 Constitution Drive
Entity Address, City or Town Menlo Park
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94025
City Area Code (650)
Local Phone Number 433-3000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol TLIS
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports tlis-8k_20211208.htm tlis-20211208.xsd tlis-20211208_lab.xml tlis-20211208_pre.xml tlis-ex101_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tlis-8k_20211208.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tlis-8k_20211208.htm" ] }, "labelLink": { "local": [ "tlis-20211208_lab.xml" ] }, "presentationLink": { "local": [ "tlis-20211208_pre.xml" ] }, "schema": { "local": [ "tlis-20211208.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tlis", "nsuri": "http://talis.bio/20211208", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tlis-8k_20211208.htm", "contextRef": "C_0001584751_20211208_20211208", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tlis-8k_20211208.htm", "contextRef": "C_0001584751_20211208_20211208", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://talis.bio/20211208/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001564590-21-059888-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-059888-xbrl.zip M4$L#!!0 ( &F!B5-]"5-SL@0 $86 1 =&QI/3E^_6*@B?,!4G9U2!P_0' #*4)8_YC-PCQ[Q"H)I MBO(59A(XX%'*;.)YS\_/;K(@3*0TE\J4<%&Z\H#C6,4?.(:: *908F"^"0C] M,'""T/&CAR".&>1?[9Z/S\3]^?^'Y%P3_%'D#EFX"QZ[N!>^Z'%<8O M$/V 2PSNIA5&-$KBT6@4AO%9.(JBBXNA'\71.$*C>#R,DZK\AS3;<+)\E. - M>FL@JOTRABG%&W!+&&2(0 KN[4[?@3N&7'!#*9AK,0'F6&#^A!-WJW4MDHDH M/*=.@XE)@LG58.NY=MCC8,DI*1,DIH9JY,4D-2Q#Z%Y9- MG:/<9'C'NH B=E.^]"S%B#A^X Q+W4)FO!F%IM1@""Z/&2A)#1;P&CTV6]"4 MN@6"CF AJ,:HB8FL\VH^/O8)80=V(MPDIRU=AD]+05U@E9H+$%#N:#7,3 MQ\()=2Z5_E]"F#6Z7Q,:+#)(D&C>LB$=;'H7,3K7JOL>>BKOI I+;/E1FC/) M-\WJM\2: 4K8CQ/Z-3F&HM2_/N!_'AKN((HBSU!+*#GGJN N;8HW7TDJZ5P\!5R@: '2 ]%1?>"V'8".@%8Q<^O6'8W-;VQ\# M=C;%H='3N=\"Q,^*1WMD1Q/83AP].0FI.?W[0JCF;3GK **>]SU1V-M2#]K; MWMVQ/2.CH0"9N6B5$8WEJZ<#RFO4C-J[H'+]]LM(RKD'.>(IQ>JR0_+C.J.0 M09F:2/0C72&"L[85(JKI]#I>9A*8?K471=V#,+1-O'U0.C#%!VA M%$*_") I75T!';;\?:/#OC7,J$-\[-XH?5U1; MF1>')GV=WYUHW8M26I?J]@(JT5@\"5X01@QV7W_ J?X]8DT!;>O2VY?85Y8+ MG/S-KLTXXU@H)<8M%>DMRRE)!"G*:0_!';+CPQ[IV/]-,<+8-Z!D^W5 M?OJUZ&4\S3"71,5(Y;%I%#QRO+@:Z']"''N,WRF,775NEN7 0/WPS*$K$4QG M.WA65A*IA6>:;$Y)O .0EJIUW%X-A$H:6KY?_O?MJE#HNMW]Z&G>]9<*5^?- MEYG8(N\D7*&=<_R?OGZJ6W7UVW*]4J7"P5E\3U?U!+ P04 " !I M@8E3D2*SN3H' #J2P %0 '1L:7,M,C R,3$R,#A?;&%B+GAM;,U<6W/B M-AA][TS_@\J^[$[7&,AE%V:3G90D':;9)!/8=J>=SHXO@F@J)$8R"?S[2KX M!MGX(A;E)<:1SOE\SI$E.<"GSXLI!B^0<43)1:/=;#4 )![U$9E<-.;<(^YARN<,OAU^>0>^ M_?9T!^X0^<]U. 37U)M/(0F !9Z#8-:S[=?7UZ8_1H13/ \$.V]Z=&H#RTJ@ M^PPZ\@_@V@D@"']ZH-/JM*UVQVIU1^U.[ZS;ZWQLGG=;YZ:.B=^N[IZ6FGXYYW3KO=CQ]/ M6EVW>];U3MVS$]??[-^GLR5#D^< O/7>A26*ZR4$8@R7X!81AWC(P6"87.E[ M,"!>$UQA#)YD-PZ>((?L!?K-&!4+W7HX$4]X1'CX\J*QH=["9;A)V<3NM%HG M=M*Z$3=?[+1_/0E;M[O=KAW^==64(U5# =NVOWVY&WK/<.I8PBJ1 D\2<-3C MX%:@+9+:0KZRDF25/28=/VLT%]QM"#0 B/1C%\ F.@?S]]6F0R=FU M90N;P(D(CG_GN!"+FD.(9P;'ZGZ8L50W64=7UM$^EW6\4:$%RYD8#QQ-9UBH M8MJO=!M1=\"-DB/HW1+/(:MC#%#\,'*99]2Q@W1!^#4<.W,<[);) M1>>PQAT$.4W9$ =:$OM@^1-$UB8/P2L)K$"^^WY !P/2I6"+/ MPIMY'S,ZS54SIJ5[5;)UYJ)/Q<+WRN6"Q@N*YF&K4[448?3?:H9O(FA?WRO-E,2_O@.*T6F64*8(B@N MI66]&%X)!E^RW&)G4C2'6YVJZ98"T9_$%3R0^,>/HEIHFJF%,:+B"[E7).-FW;ZN%%=>QQG^" M$R37$B2X=Z:%$ZWN6V>%G\8ZV )_30,DS_'3G.L"W:>0:8KCZF(?=R^8+KS$ M-E#'&+R90C9!9/([HZ_!HT3Q63%,;E MQ=41U 'Q*)M1%OZ[>AB(K4B?SL7":-FG?LF=PAZH.F+G0A\LX2G6]R#D!92! MF!M(0N/)]43N/?]TA MOEAH,2H([F"L"# M#8.8Y'UR(-_T!\$#,6;*R+.'%E+-2"NPRH64">T?$ON^.'Q@(_I**H5^L[L& MG==PAP^\Y)+K),EF6-@5IJBBOJV6@0:H8QY*_[!/>HTI#Y=9#^R1T1=$O)([ MABP,#7)O81X^]*O=04)I6/*SC%+%7RF>J::H!T)DQT,1.S2.AD?* P?_C6;E M=\]J! VBIQ //PXB.B#XC-H?YQJD&@,*VI M^$[!#0S]F0YG40EO2(25*M,L)4Q1%)<3LUX0Y2=N\.,S)24?N^_VJR;?-H[^ M4(8,(*0PYGE*INHT3Q63%,;EQ:T7U+\8"@)(^G0ZG9/X:0POFM:,SM4$58+I MSVU, ](\Q\]NOA%TKT;&B8ZKZ5TOSD.*D8<"1"9?Q(*;(0<7S;*J9S5-=Y'T MIWC- 1*2XT+[2.#7*RGENV..T(!+OR,8[=? MQ1EW"T=_^$-80,>@W7GKO@,)X?'SGBD]S9/&))F39Y;I ]REDFN*XE-B;)^[$D?P*J?@4BKY6Z?)_ M4$L#!!0 ( &F!B5.^\6V-# 4 /\L 5 =&QI&ULY5I;C^(V%'ZOU/_@IB^[:G.%N8"&75%F9H7*S""@[:HOJ\0Q8(UC M(SO<_GV/ R$PA 6FI*H4'KCEG./O?#[Y?(GO/B\BAF9$*BIXPW MQT"$8Q%2 M/FH84V7Z"E-J(!7[//29X*1A+(DR/G_Z\8>[GTP3W3^VGU$3QW1&[JG"3*BI M)!_Z3Q_1U]]Z'=2A_#7P%4'W D\CPF-DHG$<3^JV/9_/K7!(N1)L&D/KRL(B MLI%IIJ%;DOCZ KKW8X*25QUYCN>:KF_6NJXYU]6;FU\LYM[8VL0"BVBY@I3>!NEGDX@]B#0MW,"')Q8Z\QW M',@B)CPD81I&)W#A3!,H*1@F\$[FNB4%327%H@BV1F)FAX0F+>HO"2T))?#C M6Y_@J83X#PL\]OF(//L1V66 Z6(5,OV3^0%A#>.PKWU)> /I:U'M+Z- L%-Q MO7&Z** T9]<+!C1F9W.5^5T45E>2EHB@8C#19=-6:DKD0!>B?!D.B3P5YO$X M1<+^]X"+@PK#$,4TAKIZ L&3,#*=W/4YGA>%]A<4%HB.YF'*Z6IH4:>B.^!\ M48!ZO&/=,"^%Z$XJ'T8"@N'2X%HWS;NTC00H #(L'(2=")NTD]=824Q[+ MY?EWV)%0!8!_I.Q,[=SW*P#6PP+F6EQ1S4,7AC81G@^!+BF7A,V4;K MAE)$N5C6K8D\XH2$A4K#@>GG9GU)14?_<73!DEI9;>(ZO=C*52*_'!K8R,GU(K M@HJ0#O/T;; M4%(IJ>X>>.J9\5)2UU= M;7/B2)+^?!=Q_Z&.V9FPXXP0 FQ#N[UA8W;-,1NV-4KYF5^51F55;5T=^?!BXA#TQ([GN?"V7#+!#F MV;[#O=[G0A1VBX>%OQ__UW\>_7>Q2,Z^M*[(B1WR!W;&I>WZ,A)LIWVY2UJ> MRSU&?C^]O2!GOAT-F!>2(NF'8= HE1X?'PVGRSWINU$([4C#]@TQTCI+9;2K3J=:K5I69]^JUNN'AQ6SWJG7ZG:U M4ZMTG'3YIA\,!>_U0[)C[ZHN KV>QUR7#&".$=?:#V$$8!0\V7CJ")=_+J2XAE\,7_1*EFE62L#!$!I@A51^ M9UP@G7F_I!.3K*'+Y2AC2.&7T>%^"0DH6^9ADBV2Q7 8L''6+I4=56>2HHH4 MS7*Q4DX5ZE$:Y);!A)PB,@Q$MM^2V4;/?RAABBHPRBK"67T:)>6U(,+< GE9 MN3VC+]S.=,6CW);Y6552)C-[LOOY>3$ED]4)Q02)F;&'Y!(F8QD3NYXJR7A^ M&Y"0:<*.A "]'N;G3E*S1?S("\6L$CHQ2[$7#:P\:;1,H#EDGN0=EQ4Q&Q-* MWV710L")I1D@Y#[#@<>*JJ!JS"H4)G>H'"D4 MEW[5*A\\IX(ZQZC/DN?U&+*62[]?7K3M/AO0XJ3>\J=9+911R1%*$4E'8@< M$PU^(AN0J:@8R^U1N9\7RA;@3V%^@7&?2J&@GNSZ8J &$+M<*YI6T=I/55($ M*2"XEZ4>EI"6< :Z^PB3@ MP8P9,D$><(ZQC/V#&,P[OC,\/G+X Y'AT&6?"PZ7@4N'.(8,._T?1_RI@=4Q M@;_T3^XXS%,_U6_(>Z4'AG#G<^'+OTW\!XSQZ "K9+QQ A.L@Y/L%Y?V8A*? MPEO6!>(Q>[EV6#VHE4I*]E1*=/.S]JNIML^]X QPR8T+JC;\ASV M](T-%^O#.#6O(^I;BBG8+\&Z#"&*R;BOJ+H-J?0+FB0*'AHHU)\+D@\"%Y5- M?>L+[)$:X]$ /TDG2:;"%CZ.U-P@L0!.S0L_QT>E+#UC/DP0KGDA_4B,6:', MAD;,?S5L/^._*I<49&H\XV_)1^[@YRX'&5>=8KGZW&Q]RP[F9.&DI5).4W%+ M 8R[[TPT#W@I0C0&CT=6X&%2R3@M6P8T8D:))"7;F73#R;>8B6GVIWBM!3-1 MWJ,2Z#G\%_X*$G7'PD6PKGI>PP9BF?@TH*+'O6+H!XUJ$"8_.WX8^H.&"5]4 M$>XARQKFKY^ZT(/B(T-;L='Q74=_D/Q/UB@?0G;ULTL'W!TV[OB 27+%'LFM M/Z!>G!5[ BH%R.KJRD=0JU!(YWJ@@E-HD<09"\??KUIWYV>D?7=R=]XF1Z7@ M>"["4I2D2-TDPMKGS>^WK;L64'5R=4;.?V_^[\G5UW/2O+Z\;+7;K>NK%5-K M+9/:?U'9!]\M]+T]?@6U*OQW"9AD!RN5ZIKEKYETJR6B$" MPFY9X(N0["2_&87YF\F0L =<>Q(JF3F[C6>0PLI#BAME%IQKDV$AR"#:G?E< M !>HX4#I 93M.W0XA,XQ#_K.;#;H@$EUN*>6CM:++U9UF>,TF^N5:6?BEO6X MQ'K#*TA9#*?O<#&+G')_P!QN4Q>\,P%CK]S*208O2_>UW)OS\#,>BYA/?XG% M.^=/%+0AW M\DVMTTY^O$/2LY].8_[HK[H'E6K<@2#;_V>8&?_4/8'?6>[BAS%_#R?8>U0* MG0E"=4-+)U2-QWHI7=606A]D2,OKIO-]#V@IQJ1)9((VUJ&M+X#].;F0MC8 MH7W1^$7[90O/E:]O>QQ.VQXMSQX;#.T0S+:FWMMH^L[+[3]< L>5JI %PG_ M-K4!Z-)'L 7S#+_WB^535D$.J5LM6*$6'$QKP1?N,L@)SLFB*_GE8M4TJP=; MD=Z*]!I%NCXMTG?TJ15O1-@*W%\BW]7]8J5L65:M]IR ?X2Y?=:(S[74^YI> MKYJC<3G/#_M,D#\BP25X_FJ=S^\NZMZ6WS(O>-IV42P1/>KQ/]7OW?<-P7,X M%%OU6X+Z-?W!@$NI5M<^D*JA@43T#+)5K*UB+4&Q6L:MT3;(^2!P_2$3'TJ[ MLH8:N?*-W5S[*F%&7S>MMIH*L7 "+3*@()VUPJJ7E);N;LRYII3'@O6ATH?T M1,KFM"=RXCB"21G_YX)[K+R8%V)53 PZE%!9I./D!7_(745:.F)L//_+,_G? MA#^OQ9W_Z"W&_4OFN3ZYH>)^DN-[LS>7R];,?B@'YEK<"/^!JZC@5UUC;,*( M0R:/T^G=SYF=S=F3C3M[XT,+[O_Q8.'ET.-ZU;06- M P$RR /J$O;$[ C/]L!GF(F9W".0Y$;(-O(G#V!X')8W+9?4WNYQ$@\Y;_R" M->;9R^),U@0PF6!HQ)03P>CBVK&S7S-W%U#16KK9"]^F[DT?^O^B1:U*I5B! M+']U EDD-&#E,CZ.*?GMET.K?/!)DI"Y+$"F$4]Q+2W@% 912_A4D,C+@F[6 M$Q/2[#/[7@6%T0!F!=!N7"SK^$^DPUS_D7 =,?8%\I/#XC?2Y2Y2SR6P(F1 M@8-AD'O,CZ0Z)!*M<=H>J9%S [X!8Q,M.NLI4^$D$]0A"O6&2UO5= M:!S+X4S%))V>"WGP:_?PD>@JSB0E3DQ2ZC_&M65,?WW0X%(0U!5=#3 MJA]4JY_FW--:DXF2&OG:LD=^V; 5#RF,87I,29 *Y;V-0,FK5BU&EXFX5PQW MW2D?D.:76P+>D@$9-9#/:ZN\?&;;#_)BWK9@-1NLEF%#;Q!89;;7V[[+;9!1 MKW<),S%4XGYHI,HW^M\04HW'$_1.#^@T3)6KM%BV4DB5"J5D"H3#G-94G9A";T!<=[L+>I=;Q-HPQ()Q+=JI@?VID56N M.D5KI[,['W[IO%L$VR+8.A"L_@R"M:2,F-CBV(?%L0HK5O&:IGEP+,[[$AQ# M[NYO^+I@RE76"W5,,"?#LM%1607]\<(=L"F] K?"@UQ&Y7#-9[FJEO%ACG.5 MC?K:CSFM:%@MRSC<7S>MVR-=KWNDJVP<'F[4J:YE#O 41,5HG) J?9<[I!R$ M))FU'_L\9$4$:9P['@4-%MSN?M/!97=XCY>^(\#N$]NE4BY?+=.X.G-\5/\# MO!P@?,> -(6]/Y77#Q2+<2>HVG_6GM..7$%P<;ZAPQ!M3(AJ+'G-RQ;'341+A8JA.LI,.CM MT+?O]\C?3 .S$P &'-N(D0 O".QOW)'FI?LSFW( -->;^9A2GPG\C:=5/:LN M>*'01:N]6=*\/G0'QKDR245 M]RPD%Q?-.4*WYUD:W?B8R9:'%X=AF.20V"I^$GI[#X8.4P>,)X(;N234(PQ8 MTD.[O2?\Q["/:]$!!CQ221S6Y9Z^=TO'+)DU,GU1W_A^O@K90"-77BP5R]H6YVBE5-7[J5_2:6XN#TNEZK6>-.!KN?Y W"$!P@FZ%%( M4-%;AT(,3[.4+\=#?BCKX-.U9@YE2^8F$^Z@A22JCI MB['IU&/%CF#TODB[@,(-ZC[2H8Q?)/AK$1+/VBB*!Y/G2%<=/O'3:QK35F:< MN:9V J=7L&?:B7]$,N3=X>1BC)5EXOB*Z@TP!*=FH_7WJ16R 9DY6ZZ_?S7# MM#:X>T8*SF9X4ZN2WQ=1,">@:,?QC 54A)%0"X9G7,!\YPN)TV:3B9""(7RM M3A0*^=LOM?HG<7:==!($/O="%=\!J4GYB0K0L&*>I%!N2$Z$P(D4 MB\ATF:3(^!B \EKF.JXXWQC,-)\4RSD^LV6_:OS, @)XRR00,CJAU>QSU@6C M(SGB&3,'3!QG- 3/'/][,3\V)GKHVB.3UV^3'33$\'2@97XZ[W:9>ME.O4&G M/I8_[>Z14ZR(_,,@IRZ5Z VJ<#*P\-"5$BDF@]&)U=W@-Z1>L786VV%$GKNW M.M.SV(M(NJ3JI62@28FMR5,?S,\)[=,I<>E,C2KWJ#ZP4#M@&8_HYP/L$3#! M'4Z[B.]*1R;!Y@4Z\JX48B\E2U3S!@3]UH[KOKR0&WPK,"UP[<@H5GP\BY%HG:C([PIC=M3)U7Q+47L%"5- MW-@GK19QXK%*G#CP',&7 0T#>WL +F# A3KQ&Z:[.FH!&%$A)YX708%+QI2# M!YU6BV-]F&-A1D%?- XF@,[MI70'5%^0,<: M>&S5"#YSH'!'16D*Y26[ZK4DV>1/8AFSK<#YG=]X"XWA#]>T 4 MH84&*]?O9"; .CE.6@*;XZ82$91XJ08XW4&H)0[?'S3(%^$/R#6(A?Y4/D#I M.8EZT*3*L4=2I#U"F_^$RL9HOD?:U&52@_JXS3/VP%P_2!#D*_.H.PR9?O5S M#X2RSZ@;]FT*;*(JC=NZ$J5=1;];5&F MSW/ERHU7O PH'$.0@S='%?[DS[J MM=M88IN@8;S;)=>>K1@L0 ME_^(N(/C%,CA>"6FB[R$MD !\-T^[.(E'2JNQHP>(8MEFH!_@^2>2I!5PCS1*HAG$E]^04[P,#70$C0=&A^'X6 MW3/RW>/JS=Y0:POHWZ5Q:IP8.@NJR_?FQ0G &"H?=M;N^[Z+9&A:L5<&N1L! M<8>Y'/J+F@:P..[-2-M2RKNH/BIUYE*OO4D$Q9?A ]:3UI,17F3\OU-JW_>$ M'WE.,0;-+^H?8->/"*_& 0GA@_'4$2.V8H,QUQK46X+K>5G3PJ/7GA>[94K# M0 CT0M&$)-"4T43E+$-@+V,&J)T[M24"?*?HD'1!,%P6XAN:>:UI.>SY(.2> M%C>*E%2=^2I+JC2J;8,.43WO MXZ.,1%*7"G6%Q=]J5FT/1C+1M3A7"#( BM[Q/0 O]D-]\LE![=>DF].U933] M$4T?ZDIM?WOJN5%E$]FQ!PMC#!BB%0@ 4F,A'W0B(6-WET^/&S;\R-@]0&%< M7F&"=E<&H%#DT1?W6)?KQ]?M09-X*4K6=AL->)?:"+P*I])O:TWR=&^*-B"K MAROR"LRDVEWT ]7B,PO9A6.H.XA@ND"V56NFXKR*,9ET:L;8DXI2B0=3HUO< M7-(;CB>"LHOS,TS ,CF'J0_@%>87'!J0[!M7#;VC:WO MZ90/H&TKA^)(EH_ M\5["GAX)2TL"MA!W7T:=/V"L%/I$,!_&W<.ZU*2ML0C&0M<&\J-@/A;#:?,Y8P.RM!#!N M?P/)]4C:EL%+Y+01Z^F[@=K% M,MG1=][Z!JE4*D6K9E7V33 2=3,CW$WM0RL+)]G7&M\3K"IE'1&A',>NYF[, M5?W_H*IH(,/_/%]OS='X*J ."P',O"FG,@4U:JH0^/2S,J2E[?H2UR+UJ2^U MCETUJ_'6&Y =N3'1Q6]@K48")PHU0P@$".P!':\HXB*FJDCM\:$R)#U*]4!/ M"\-XS@F4R94]CZ;':,)ZE\DF)97QI#BRET8N;!;PWI'^W2F$$:SG(U-A)K8% M#Y+5RAP#-#-[JV$*]78MBV$0OFD#+_7F&2*W8(#B';2KXX>4$XW SB;\S'U&8D,#XZ>8HP49U#E*N5;ORM?[MC$[=@E.;7#;-LY&'V(K$AZZ?E MRRCL8 35"F[GF8T2X96OM,/^3-S@4C;N5XU,.\ZNIBCAV\_6[UZ@I3_?E%_A M4=M9F_$3T:V=6492-APT)Q;T8#H6]" O%G04"'I@',XX):1+KO*@T-P(L-0W MKV-9?(4;.M\*Q?IBT_D"KU]?-)-C!/NSCJO%@KC4ENMK!;*M-CSSXDO5J->" M\:,O>8&CJT:Q]=V[M>QQP>6..L:GW1S:8YA8-O$K786GI"_P3$'H M[D8MX[F^>^5;$%IK:!4W2R]7+'1M'*&?R0LW!BF-]4^[ WM,=)" M%Y6.=GTI4?MR.^< <(X3;\7%6XHM#T&1_'YZ>T$-R;K,G-YW('1*;1GC:,M11*VI[38>I8_0O)/AZ?Z_#^M3MXMR.%>E]6IT! M=W,CC#92U=$H[/L"6.;,VD%]$^Q_:_<>K^JBSNJR;W2MZY?@U<'PNHA=Y[USRU'OUE"U6OEW1VDB@7">IHV>'*VM_=GB5^]#+]7CO3BY:;7+:NKX\/VLU M3RY(\_KVYOKVY*YU?377FJH53"^HKF@FVPAAM I;LK=DOT.RWY^QMIU1MT;2 M=D@WG>%7B5M_'4&*:%9[[TW)5G"&XUN?;ST MX-+WG>$>^8?(VR;<3M+OG]3MD+X[4K=#NB5UDTC=&--K.^N]7R';DKHE=:NH M6U(WC]0-\*3+*B,^7]3DZU]-\$)*CDH=,#(43_OAP(4_ M_A]02P,$% @ :8&)4_P]VP:*$@ ]W$ ! !T;&ES+65X,3 Q7S8N M:'1M[1UK<]LV\OO-W'_ N=<;^T9O/^NXF4DYMO$D[G3ZZ08B(0D-2; M:5GWZV]W 5(B*8N"[21V+NU,+)%X+'87^P9T]K69>EIOS^? MSWOS_9[2T_[UN_XLBZ.#?J24$;TP"W=>_O4O9_B,_@H>XM],9I& #UDD35?< M#@?#_QSUH!&\ZA?OSOI%Z[]UN^R7']FY2FZ$SH1F-X>]06_4.SIFW2XV&*MP M 7__?F/9&S2 M%V?]].47#,(K+7E4GYB^S@4.?IHH'9M,Q;C-P&XYXR]PZV8)(!AA:Y-.SS9 M;N%VJE'!%$VN>40V.9/QE!D=?+\SO16'>C!,/T3!>(#_#7M_I-,=1E+D^YT= MQJ,,_[C%SF68S4Z'^T?I[8N9A8<^PY!^6&GGAD!%2I]^='W&5V MAF^*144B R'1-2D/9#(]+20N.^MCJY?2;&Y]4&D]E]FL9?3J\%,M> L\U1D M:[/<2&[BS;V.*KVR6=LL^U6XKD&">JW\M52Q"&7 (Q_LGBN=*LW1-MW4;=@; M5;KM_N.;D]%H\(*@I,_#%S[3*MV"C!KRA!=-'7#G*DYYLG#@[6T>XL2+Z0;5 M"5.M;F0(KS;W&E8Z+53>TKPZ"=](H08#JIU,2K^?E,BHT]FDBYN!5! MGLF;%IZM]7H[F7A<\WV$YR'E-X\#TL<%^V6PS>W?W:[N=6(G95HR#Q!1$Z-597Q5/ MES/S!-@">@:("\;=U(*%/!,,F)_-.#PW8"<"_T!C+W1ID>4:.^)B6#E[#6<5 M$"]*6-X ! 6,3UHMA &C M9Y&!X$AR:#1626Y8BP);LT= >!1JA,'GX\-O<=4-K" Z.K!6H&R"HAE6 (:6 M2$)N48*.XJC'?E#T:4BRP0L2PF6A3I$(8\$$^-!R' E<%N,LE :(1E%$@*BR M;BOD"6IQ*PUICZ5&]A-.&EAJ:H4I2G"+9H/R>QV-2#_BTUCH 'B7.3W68Z\B M(AT.9'!!OAB9:!579+EC-V;R\1\@-7!,DW$D05CR2"C"/$ 4&0(>)&T$%C'B M$+ELIB(TTHR?S/\=Q'R M:Y;'T)9$L0=_K=6R&9(UM@@MPD^'H?B%G0RLZ:4QQ^!Z)L( &C583]%ST8)/ M(5YS79RL;E0%T;K^!:9T"U#FWYJX5^JE(C)\56JZ>1'VJ M0%#2%@+^+S4M2GU8MK4)F[O%3XZ^PL%+\QEUETC$1&9^,JBA$4#T$_UP[%CE MY(!FH)FMH1.HFT(SSA3NG2D:+Z /^!SZE13V H&X 0F&HX'(N5O %):2 ZP4 MTF.RPY2338!L5.6!,IF?7P967*ZU]9XL,H!8":B:&R0IS!,K+:P0_/LQ6G%D MPL70=>9L*,OH%5;P"WP4"AXA*! ,BU1S,NUBP'%58Z]HY)JN7E70?A;+9M>Q M*7H14WX]EFOP],%@P5[B/>.W?M&0J59F,],T@,K33INN71.D 1F3M7!'W]?$4M]7VJ!"] M<%.3T'BLLHKZE%C@ MI(M)4SX5W3$X2!^Z? *X.N41&&OFA:M &, T.U]RN="3*KEYBC/>*Z]>4WEU M !ZO+J&BB4>]X1/0Q*]:E>I)/:$I6W.!Q[7$P9^YS%JGJ4K'.==AFW0\KD,F M;B0X&I'?5%/ 4TO&!>?RTP[5YBT!SFZ])& +-Z2V]B(^_#%7T1+/KS>?HG^= M>")V[$>[]JQ2%;%+']/+A+@' X,##ENZ/7]577X:;4[EXX)\7=RCNEO(6WVU M*E"A"G)RO38&=48U^^;2=R%%\M0+MNU\[R,?WVX-:"D&KS=7SS2WY..S#6_BUFG2OY,R9D\F,P\PJ MV.@D-,LXTE87H;[.W7;DUXCK"@?>TES;E!$UZ>TG?--<@W>Z.9#;Z'1P.,#8 MGM^.FG'=ZO=5E[(YRMT0PM[(KB6M?#5C'+>S0RTXA4RW6=I5VK>',VH3O&WG MT?VZ'U^&B'G"2NUB]P>S/%]DZ&-^*^,\=G$YC.S&TAC*%]MT\'M!T55V,!IM M4YM1W^:76+J-8?IW&$[.,>H>TBX??G=RU,', (\IS&Y#R>(6$\!&8" \$!1H M)B8KY()%A@V!>\&!6=<_,3[NUAU$BJ+,=AX8W=*^P-&DDG5T4BATU0PD<7KL M?1F/]H*$@O7+DC?,9U*2I%ISU%E=+HFZ&V$R1GD(?#.!4;I4,P XDLJO"&BB M,+9.Q6$-X8HDL>_-*J$"^%"D@G#;$GJN2\65W8".C2LSQ?&G,*N&C;Y8S?H5(!4)YQ[#ZK3(J!4, MV7K3C9FS!D8.!L/=#WNVF(R7L\0\P_3K$B^<76%Q#D9_L%2)[5Y=O]W#LA78 MZ;%-?N/[+3(1:]+"D0SYXA[51<14/ @TL!3 PUSI3%&#=T!U"0;D]X#A!'LK ME7B/)XN\XMH I5]>KR@O**L)O'((:RH/GH?8.CQX0F)K553A;N4Z Z*DR&72 M6@)TG(,M3Y*PE>,A8$^"BJ:TOBW^PBQ:2['_&M\QR;2*2,-U"CZW-81EV7Q1 M0L@BF#"J%KLLZ]@1!I##-IQ Q<=^\F*Y^HH:9;MRPFPHP-55"((+OHP7I>1< M,??VZ &)6]\B\$(DDMAM/A0K"PL*W2OCZ-P& M[B:_"T'PRBJ7E&A(.WN!3VLX=):P%RC.X;XB %XM*U'-\E0!#)E8.@0?$C6/ M1#BU#$G3%W6'P,5+<$P.\M*(D*J;_&3Z55LD6\N6:S/@R9C:[2K7FG#@6N]<."),I""\#B79G:/,R3$1;"/$L4B!2C4 MU1T% I2A09Y%MI2LLL.6VZ"V?>!9[&T!^#D]N::)-VX \)-)0!>EUWJE'IP, M12,R7"582R3[/0^\E0=NP'I5@*D,9;$!7(&D+,[;_*A4R-Y1F:O;OLS)*8NX MJ5: ,E.:I%0.C,>!_"ORMJMU;U9-^)YW(\#GLC5 5^\VSGB+HFR63FTCRYLK M*KC1R[PBSO4LN6HOT_$3I,TI5@7;<['WGL)IGRLZYH.;TDF#6MQJY:AF_>@- M'H&QHH^95 1R(C'V06&J-NG:,/66 L&SFL^)#PY( :MUB\/%S5VP7.)&4=SL M^*K5#:IM [^E@7S+H\T%S\UZH/:\>/(58;XPV4,A7ML,=JO;L;9SC[V7(%RXCEPD>G5KDX&@R(.2"?E]8+>L MR ,M(GL 8293UGZ50M.>\D1/UF:0K^$\.J7C/!Z_KA9!K)6(3:JOH/M2HE M?W$,=:7ZHI[!N 5K+W-N[EB& H-=Y2>DV] KH,_:0TR!=%V961L;H__XND( M4+N.QK=!E!M;Y0 FB8TQ3CR1LP@.#ECK@4D2 &*T2&>!1_8CMVA0Q5;F$DR)JMM(* M23CB_>7/_["7@6TLM%@,.BP7Q-)I007R_'H M@EKN#F-2XR*Z65WFWO(%21>J. )ZQ+!S;(A@29H0,4%\1/?\C 7P;9AC,AAS MU\A5\/D._)# %[95[1XALOSQV&^N@2+BKLC0O2S&A]SUV2+_#X:]X4%- >"S M)W XX)]^3ML_V<8.:]L_]@6A-1Q]04[0_ET:=IVOX&.DNI M#Z@R\*"1O0Z"#$II;]>CNQH*.]==89"*I9N8 (,,X5& 7HO M:.GA;#@%::[D#[4@_8E.EI8B">ZJ7KG/!M]_ !$?,NHS]WI>8^GI.S'%\V=W M7-[[R5;X?^5N5DP'ZA>*P%48G9)E'8'[ 0W[IL]^ .OPEKWF'X1VQL26W5=1 ML6_/)10#?(E(7<736+/^2_!8);Q+*H=R*E>&VG:;ZKT^,:8^H\AYB Q]X-3M M-Z)_M%5_FMOHWVYQ"W'-8?B)&GCF;8- I!F52]Q]@<'A\S5E+KU2I^AP>W4 M'Z#MD*%7F=::1#D1R(\16N\IKD.US9777M=!-V986G^GGWB[/D+9RGTG"N4- M(Y\+\3/)T"?,R*(=*PT:]_N=P0X+1!0YK)7?4SSMZ[X[4&V/;J"BB*=&G!8? M7C#6Q(_[08I!;_2=]40SC?^$Q6#V_6A$"T(-GX5KW@][QP<;7A_W3D8;7H_@ M_5@AP&3P4P>S:0?4,_PS&HNM5>G(/?6^F);3ZY MB$*#S?X:!OLW$%\LD'F66 5* W\ LD8[5;Q]5E1LLKV7L'^E<^5G3P(1 YG9 M2:?\>9RUN^-.BM&/@TR-VR8+VJ3_!^3&,]L-/9(GQ0H/ /= M^D2LB.<8+3_XN-'RL[[[><2SOOL9QO\!4$L! A0#% @ :8&)4WT)4W.R M! 1A8 !$ ( ! '1L:7,M,C R,3$R,#@N>'-D4$L! M A0#% @ :8&)4Y$BL[DZ!P ZDL !4 ( !X00 '1L M:7,M,C R,3$R,#A?;&%B+GAM;%!+ 0(4 Q0 ( &F!B5.^\6V-# 4 /\L M 5 " 4X, !T;&ES+3(P,C$Q,C X7W!R92YX;6Q02P$" M% ,4 " !I@8E3WT>MCF47 !OQP % @ &-$0 =&QI M#$P,5\V+FAT;5!+!08 !0 % + $4! #<.P ! end